Mogrify strengthens leadership team
Cambridge-based Mogrify Limited announced the appointment of Tom Graney CFA as Non-Executive Director, Audit Chair and Capital Markets Advisor.
Graney joins the biopharmaceutical company as an independent member of the Board of Directors after many months of ongoing support.
His industry experience comprises time as CFO at Vertex Pharmaceuticals, Ironwood Pharmaceuticals and Generation Bio after many years at Johnson & Johnson, which includes four years as worldwide Vice President of Finance and CFO of Ethicon, part of the J&J medical devices companies.
Most recently, he has been appointed CEO-CFO of Oxurion, a clinical-stage biopharmaceutical company developing next-generation ophthalmic therapies. Graney, Chartered Financial Analyst, Certified Financial Manager and Management Accountant, brings a BS in accounting from the University of Delaware and an MBA in Marketing, Finance and International Business from the Leonard N. Stern School of Business at New York University.
After the recent appointment of Dr Louise Modis as CSO, Graney strengthens the leadership team and the company in the financial sector.
Eppendorf
NOD-Proteindesign.Andreas Heddergott/TUM.jpg
Certest